Aventis/Novartis Merger Would Infuse New Blood Into Novartis' Cardiology R&D
This article was originally published in The Pink Sheet Daily
Executive Summary
The combined cardiovascular portfolio would be a strategic fit since Aventis has focused more on acute indications, while Novartis has targeted chronic conditions. Oncology would be largest therapeutic area.
You may also be interested in...
Novartis, Cephalon Disease-Modifying Parkinson's Drugs Near Late-Stage Development
Novartis' TCH-346 is slated to enter Phase III in the second half of the year; Cephalon/Lundbeck's CEP-1347 is in Phase II/III. Both drugs claim inhibition of neuronal cell death as the primary mechanism, but will need long-term trials for disease-modification claim.
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.
BeiGene’s Tevimbra And The End Of The COVID Inspection Era
US FDA approves the PD-1 inhibitor 20 months after user fee goal, resolving one of the last applications delayed by China’s extended pandemic travel restrictions.